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Abstract
Purpose: Hyperbaric oxygen therapy (HBOT) is used in the treatment of radiation-induced tissue
injury but its effect on (residual) tumor tissue is indistinct and therefore investigated in this study.
Procedures: Orthotopic FaDu tumors were established in mice, and the response of the
(irradiated) tumors to HBOT was monitored by bioluminescence imaging. Near infrared
fluorescence imaging using AngioSense750 and Hypoxisense680 was applied to detect tumor
vascular permeability and hypoxia.
Results: HBOT treatment resulted in accelerated growth of non-irradiated tumors, but mouse
survival was improved. Tumor vascular leakiness and hypoxia were enhanced after HBOT,
whereas histological characteristics, epithelial-to-mesenchymal transition markers, and meta-
static incidence were not influenced.
Conclusions: Squamous cell carcinoma responds to HBOT with respect to tumor growth,
vascular permeability, and hypoxia, which may have implications for its use in cancer patients.
The ability to longitudinally analyze tumor characteristics highlights the versatility and potential of
optical imaging methods in oncological research.
Key words: Hyperbaric oxygen therapy, Radiation, Optical imaging, Near infrared fluorescence,
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Introduction
H ead and neck squamous cell carcinoma (HNSCC) isthe sixth most common cancer type worldwide and is
associated with a poor prognosis. Treatment of these cancers
often involves surgical resection followed by radiotherapy.
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Despite advances in radiation protocols that minimize the
targeted tissue volume, radiation treatment often causes
considerable damage to the surrounding healthy tissues
resulting in complications like impaired wound healing and
osteoradionecrosis. Hyperbaric oxygen therapy (HBOT) is
frequently used in the management of radiation-induced tissue
injury, and has shown beneficial effects although its working
mechanism has not completely been unraveled yet [1, 2]. In
HBOT, patients inspire 100 % oxygen at elevated barometric
pressure, which enhances the amount of oxygen that is
dissolved in the plasma leading to an increase of the oxygen
tension in tissues. By creating an oxygen gradient, HBOT is
thought to induce neovascularization by which the progressive
loss of the microvasculature in hypoxic irradiated tissue may be
overcome and tissue healing is improved [3–5].
The use of HBOT in patients with a history of cancer has
often raised concerns about the promoting effect this therapy
might have on the growth of (residual) tumor tissue. Poor
oxygenation and abnormal vasculature is a common feature
of solid tumors and reduces the ability of cells to divide. It
was anticipated that by its pro-angiogenic effect, HBOT
would stimulate cancer growth and recurrence [6–8]. On the
other hand, tumor hypoxia is known to be essential for the
progression of cancer and is related to increased cell
survival, induction of angiogenesis, metastasis, and therapy
resistance [9, 10]. Enhanced oxygenation of tumors by
HBOT could therefore lead to less aggressive cancer growth
and a better prognosis. Based on clinical and experimental
studies, it was recently adopted that there is no evidence that
HBOT has a cancer-promoting effect [11, 12]. Even more,
on certain cancer subtypes like gliomas and mammary
tumors, an anti-angiogenic and growth-inhibitory effect of
HBOT was reported [13–15].
In most studies in which subcutaneously implanted
squamous carcinoma cell lines in mice were used, no
differences in growth between control and HBOT groups
were seen [16–20]. However, in a recent study, Paniello
et al. [21] reported enhanced growth of HNSCC tumor cells
in C3H mice after HBOT. These divergent outcomes suggest
that the choice of the experimental model, regarding cancer
cell type, tumor location, or HBOT protocol, is critical for
the proper determination of tumor responses to HBOT.
One of the tumor conditions that is relevant to the clinical
situation but has been scarcely investigated in experimental
HBOT studies is the irradiated tumor. Since radiation not
only modifies the cancer cells but also the microenvironment
of the tumor by affecting angiogenesis and the hypoxic state
of the tissue [22], previous irradiation might well influence
the response of the residual tumor to HBOT.
By using an improved, clinically relevant tumor model and
advanced optical imaging strategies, we intend to increase the
insight on the effects of hyperbaric oxygen on tumor growth
and factors that influence tumor behavior like tumor vascular-
ization, hypoxia, and differentiation. In the present study, we
used bioluminescent imaging (BLI) to non-invasively and
adequately monitor the growth of a human squamous cell
carcinoma line (FaDu) in the floor of the mouth of immuno-
deficient mice. Near infrared fluorescence (NIRF) optical
imaging was applied to detect and quantify the effects of
HBOT and irradiation on specific tumor characteristics in vivo.
The fluorescent blood pool agent AngioSense was used to
analyze tumor blood vessel quality, and the NIRF targeting
probe HypoxiSense was applied to study hypoxia in the
tumors. Furthermore, this orthotopic mouse model allowed us
to investigate the effects of HBOT on the development of
regional and distant metastases, which are likewise frequently
seen in patients with HNSCC.
Materials and Methods
Mice
All animal experiments of this study were approved by the Animal
Experiments Committee of the Erasmus Medical Center (DEC
2645). The Dutch Experiments on Animal Act is established under
the European guidelines (EU Directive No. 86/609/EEC regarding
the Protection of Animals used for Experimental and Other
Scientific Purposes). BALB/c nu/nu female mice (Charles River
Laboratories), aged 8 to 11 weeks, were kept in filter-top cages
with autoclaved pellet food and sterilized water without restriction.
Mice with tumors in the floor of the mouth were given soft food
and were monitored daily. Animals were euthanized when they had
lost more than 20 % of their initial body weight or had reached day
35 after tumor implantation.
Tumor Generation
The human hypopharyngeal squamous cell carcinoma line FaDu-
luc2 was kindly received from the laboratory of Prof. C.W. Löwik,
PhD (Leiden University Medical Center, Leiden, The Netherlands).
This cell line had been transfected with a luciferase-expressing
vector (pCAGGS- Luc-2) allowing the monitoring of the tumor
growth by bioluminescence imaging (BLI) [23]. FaDu-luc2 cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM,
Lonza) supplemented with 10 % (v/v) fetal bovine serum (Hyclone)
and antibiotics (50 units/ml of penicillin and 50 μg/ml streptomy-
cin) at 37 ° C in a humidified atmosphere of 5 % CO2 in air.
Orthotopic tumors were established by transcervical injection of
1×105 cultured FaDu-luc2 cells, suspended in 20 μl serum-free
DMEM into the floor of the mouth of anesthetized (2–4 %
isoflurane) nude mice.
Hyperbaric Oxygen Treatment (HBOT)
Treatment with hyperbaric oxygen started at day 5 after tumor
implantation and consisted of daily sessions, until the end of the
experiment with a maximum of 30 sessions. The hyperbaric oxygen
chamber used in this study was custom-built for small laboratory
animals (Hytech BV, Raamsdonksveer, The Netherlands) [24].
Each session started with a compression phase of 15 min, during
which the pressure in the chamber was elevated to 2.4 atm absolute
(ATA) and the oxygen level to 100 %. After 90 min of isopression,
decompression to 1 ATA took place in 15 min.
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Radiation Therapy (RT)
Mice were anesthetized (65 mg/kg ketamine and 10 mg/ml
xylazine) and locally irradiated at day 5 after tumor implantation
with a single dose of 5 Gy using a Gammacell 40 Exactor Cs-137
γ-source. With this dose, tumor growth is significantly reduced, but
not all tumor cells are killed. Mice were shielded using a
Gammacell 40 Collimator centering the head and neck region in a
3-cm radiation field.
Bioluminescence Imaging (BLI)
Tumor growth was monitored twice a week by bioluminescence
imaging using an IVIS Spectrum Imaging System (Xenogen). An
aqueous solution of luciferin (Caliper Life Sciences) at 150 mg/kg
was injected intraperitoneal 10–20 min before imaging. Animals
were anesthetized (2–4 % isoflurane) and placed in a dorsal
position during imaging. Using the Living Image software 3.2
(Xenogen), photon flux was quantified within a circular region of
interest (ROI) encompassing the head and neck region of each
mouse. For 3D reconstruction, bioluminescence imaging (BLI)
images were coregistered with computed tomography (CT) images.
Fluorescence Molecular Tomography (FMT)
Imaging
One day prior to their endpoint and at least 20 h after the last
HBOT session, mice were intravenously injected with 1.3 nmol
of the fluorescent blood pool imaging agent AngioSense750
(PerkinElmer) and/or 1.3 nmol of the carbonic anhydrase IX
(CAIX) targeted fluorescent imaging agent HypoxiSense680
(PerkinElmer) or MMPSense680, a probe that is activated after
cleavage by matrix metalloproteinases (MMPs). For quantitative
fluorescence molecular tomography imaging (FMT 2500,
PerkinElmer), mice were anesthetized (2–4 % isoflurane) and
fixed in a definite position in an animal imaging cassette. The
FMT 2500 tomography software was used to quantitate
fluorochrome concentration distribution of AngioSense in a
ROI of 750 mm3 in the tumor area. In vivo imaging sessions
were performed 2 and 24 h post-injection and hereafter, mice
were euthanized (isoflurane overdose) and the tumors were
dissected for ex vivo imaging. For multi-modality imaging,
image data from FMT were fused with CT using markers in
the multimodal mouse bed.
Histology
Mouse tumors were fixed in 10 % formalin, embedded in
paraffin, and 5 μm slides were cut. Routine hematoxylin and
eosin (H&E) staining was performed and assessed by a
pathologist. For immunohistochemistry, slides were probed with
primary antibodies against Ki67 (Novus Biologicals Ltd.) and
CD31 (Abcam) to assess proliferation and blood vessel density
and diameter, respectively. Biotinylated goat anti-rabbit IgG
(Dako) was used as secondary antibody, and detection was
performed with streptavidin–peroxidase (R&D Systems) and
3,3 ′-diaminobenzidine (Dako). Hematoxylin served as
counterstain. Slides were scanned using a slide scanner
(Hamamatsu Photonics). To measure proliferation, the percent-
age of Ki67-positive cells per tumor area was determined by
using Celld (Olympus Life Science Europe GmbH). Apoptosis
levels were determined by counting the number of apoptotic
cells in proliferating tumor areas (×20) in H&E-stained slides.
To determine vascular density, CD31-positive blood vessels
were counted in 20 representative fields (×40) for each tumor.
The vascular diameter of 30 vessels for each tumor was
measured in ×63 high power fields.
Metastasis
During the course of the experiment, the development of
metastases was monitored by BLI of the total mouse body.
Imaging was performed using unmixed emission spectra,
allowing signal detection at particular tissue depths, which
prevented outshining of the signal of the regional metastasis by
the primary tumor. To establish the incidence of lymph node
metastases, two superficial cervical lymph nodes were resected
from each mouse, incubated for 10 min in luciferin solution
(30 μg/ml), and ex vivo BLI was performed. To confirm the
metastatic lesions, lymph nodes were embedded in paraffin,
sectioned, and H&E-stained.
Quantitative Real-Time Reverse Transcription
Polymerase Chain Reaction (qPCR)
Mouse tumors were dissected, rapidly frozen in liquid nitrogen, and
stored at −80 °C. Total RNA was isolated using the RNeasy Mini
Kit (Qiagen) and reverse transcribed using the iScript cDNA
Synthesis Kit (Bio-Rad). cDNA was amplified in 40 cycles (20 s
95 ° C, 3 s 95 ° C, 30 s 60 ° C) with a Bio-Rad cycler using Fast
SYBR Green Master Mix (Applied Biosystems). Specific primers
(see supplementary Table S1) were used to amplify cDNA of human
vascular endothelial growth factor A (VEGF), carbonic anhydrase
IX (CAIX), E-cadherin (CDH1), Vimentin (Vim), snail family zinc
finger 1 (Snail), transforming growth factor beta 1 (TGFβ1), and
the internal control glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Each PCR reaction was performed in duplicate, and
the average threshold cycle (Ct) value was used for relative
quantification of gene expression with the comparative Ct method
(ΔΔCT).
Statistical Analysis
Data are expressed as mean values with standard error of the mean
(SEM), and were analyzed using SPSS PASW 21.0 for Windows
(SPSS Inc., Chicago, USA). The Shapiro-Wilk test was used to test
for normality, followed by the Mann-Whitney U test for the
comparison of non-normally distributed data, while Student’s t test
was used for normally distributed data. pG0.05 indicated significant
differences. Survival data were analyzed by the Kaplan-Meier and
log-rank tests for survival distribution. The Fisher’s exact test was
used to analyze differences in the incidence of lymph node
metastasis between groups.
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Results
Effect of HBOT on Tumor Growth and Mouse
Survival
FaDu tumors were implanted in the floor of the mouth of
nude mice, and the growth was monitored by biolumines-
cence imaging (BLI) until they met criteria for euthanasia,
mostly due to weight loss. As shown in Fig. 1, the increase
of the BLI signal was significantly higher (p=0.023) in the
group of mice that had undergone daily treatments of HBOT
compared with the untreated group on day 18 after tumor
cell inoculation (Fig. 1a, b). The mean doubling times for the
BLI signals of the individual tumors were significantly lower
in the HBOT group versus the control (2.15 vs 2.47 days,
p=0.006) (Fig. 1c). In irradiated tumors, the tumor growth
rate was delayed compared to non-irradiated tumors, but no
significant effect of HBOT was observed here (doubling
times 3.46 and 3.65 days) (Fig. 1b, c).
The median survival periods for mice in the control,
HBOT, RT, and RT+HBOT groups were 23, 21, 27, and
36 days, respectively. There was no significant effect of
HBOT on the survival of non-irradiated mice, but mice with
irradiated tumors had an increased survival time if HBOT
had been applied (p=0.003) (Fig. 1d). The maximal BLI
values measured at the time of euthanasia were higher in the
Fig. 1 In vivo effects of HBOT on tumor growth and survival time in FaDu-luc tumor-bearing mice. a Bioluminescence imaging
(BLI) of representative mice of the different treatment groups on day 4, 11, and 18 or 19 after xenografting tumor cells in the
floor of the mouth. b Increase of BLI signals compared to day 4 after xenografting tumor cells (9–12 mice per group). For the
fold change numbers, see supplementary Table S2. c Mean doubling times of the tumors based on the BLI signals measured
between day 7 and 18 (no RT) or day 11–22 (RT). d Mouse survival time analysis using the Kaplan-Meier method and
comparisons using log-rank tests. e Mean BLI signals of the tumors at the endpoint. Error bars indicate SEM. ** pG0.01;
*pG0.05. RT radiation therapy, HBOT hyperbaric oxygen therapy.
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HBOT group as compared to the control for both non-
irradiated (p=0.020) and irradiated tumors (not significant,
p=0.176) (Fig. 1e).
Effect of HBOT on Tumor Vascularization
and Vascular Permeability
Vascularization of the tumors was analyzed by investigating
the CD31-positive blood vessels in tumor sections. The
mean blood vessel density was slightly increased in
irradiated tumors (1.2-fold, p=0.014) but no significant
effect of HBOT was observed (Fig. 2a). The mean tumor
blood vessel diameter did not differ between the groups
(Fig. 2b). mRNA levels of VEGF, a key factor involved in
angiogenesis, were significantly increased in the irradiated
tumors (1.3-fold, p=0.000), but not affected by HBOT
(Fig. 2c).
Tumor blood vessel quality was analyzed in vivo with
FMT using AngioSense750 as a blood pool marker.
AngioSense remains in the vasculature for 0–4 h, and
therefore the signal detected in the tumor area 2 h after probe
injection is a measure for the tumor vascular volume. The
degree of AngioSense retention in the tumor area after 24 h
is indicative for vascular leakiness [25, 26]. In Fig. 2d, the
site of accumulation of AngioSense750 in and around the
tumor is shown and coregistered with the signal of the probe
MMPSense680 which indicates the tumor margins. For each
individual mouse, the ratio between the 24 h and 2 h
AngioSense signal was determined and probe accumulation
appeared to be higher in the mice treated with HBOT in both
the non-irradiated (1.3-fold, p=0.042) and the irradiated
Fig. 2 Effect of HBOT on tumor vasculature. a Quantification of the tumor blood vessel density. b Quantification of the tumor
blood vessel diameter. c Relative expression levels of VEGF mRNA in the tumors. d Multimodal FMT/CT imaging of a FaDu-luc
mouse 24 h after injection of MMPSense680 (red) and AngioSense750 (green) to detect tumor margins and region of tumor
vascular leak, respectively. e Representative FMT images of tumor regions in FaDu-luc mice of the different treatment groups, 2
and 24 h after AngioSense750 injection. f Quantification of blood vessel leakage in the tumor regions. For each animal, the
24 h/2 h AngioSense signal ratio was determined (n=6). Error bars indicate SEM. *pG0.05. RT radiation therapy, HBOT
hyperbaric oxygen therapy.
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group (1.3-fold, p=0.078), indicating an increase in tumor
vascular permeability after HBOT [Fig. 2e, f].
Effect of HBOT on Tumor Hypoxia
In tumors of irradiated animals, a clear increase in mRNA
levels of the hypoxia inducible factor CAIX (2.4-fold, p=
0.000) was observed, but no significant effect of HBOT on
CAIX expression was detected (Fig. 3a).
Tumor hypoxia was further analyzed by FMT using the
CAIX targeted fluorescent imaging agent HypoxiSense680
as a probe. Because of the low fluorescence levels, it was not
possible to obtain in vivo data regarding the hypoxic state of
the tumors. Mice were sacrificed 24 h after probe injection
and analyzed ex vivo (Fig. 3b). HypoxiSense signals were
detected in none of the control tumors but half of the HBOT
tumors. Stronger HypoxiSense signals were observed in the
tumors of the irradiated animals with again the highest
fluorescent levels in the HBOT group (Fig. 3b, c), indicating
that tumor hypoxia is increased after HBOT.
Effect of HBOT on Tumor Pathological Features
and Metastasis
The tumors were rated as poorly to moderately differentiated
squamous cell carcinoma with moderate infiltrative borders
for all experimental groups (Fig. 4a, b, c). Perineural growth
and vascular invasion of tumor cells was evident in several
tumor sections but no significant differences were observed
between the HBOT and the control groups. The degree of
necrosis (Table 1) was highly variable among the tumors (0–
42.2 % of the tumor area) and was related to tumor size, but
no significant effect of HBOT was established. Tumor cell
proliferation and apoptosis levels were also not significantly
affected by HBOT although a trend towards decreased cell
death after HBOT was observed (Table 1).
To investigate the impact of HBOT on epithelial-to-
mesenchymal transition (EMT), mRNA expression levels of
the malignancy markers E-cadherin, Vimentin, Snail, and
TGFβ1 were determined. Vimentin expression was slightly
upregulated in the irradiated tumors (1.4-fold, p=0.039) but
its levels were not significantly influenced by HBOT
(Fig. 4e). On the tumor expression of E-cadherin, Snail,
and TGFβ1, no significant effects of either RT or HBOT
were observed (Fig. 4d, f, g).
The orthotopic tumor model allowed us to identify and
monitor the development of regional or distant metastases in
real time by in vivo BLI using spectral unmixing and 3D
reconstruction to circumvent outshining of the signals by the
strong total BLI signals of the primary tumor in the floor of
the mouth (Fig. 4h and Online video). In the time frame of
the experiment, distant metastases were not detected but
cervical lymph node metastases developed in the majority of
the mice. To confirm and characterize the metastases, two
superficial cervical lymph nodes of each mouse were
harvested immediately after euthanasia and analyzed by
ex vivo BLI and histology (Fig. 4i, j). For the non-irradiated
as well as the irradiated mice, the metastatic incidence was
not affected by HBOT (Table 2). Also, no effect of HBOT
on the histological stage of the lymph node metastases was
observed.
Discussion
In this study, tumor responses to HBOT were investigated in
an orthotopic mouse model of head and neck squamous cell
carcinoma using optical imaging methods. By means of
bioluminescence imaging, the growth of a human
hypopharyngeal carcinoma cell line in the floor of the
mouth of mice was accurately monitored and revealed a
small but significant increase in tumor growth rate (19 %)
under the influence of HBOT. No effect of HBOT, however,
was detected on the growth of tumors that had been
irradiated before. The difference in response might lie in
Fig. 3 Effect of HBOT on tumor hypoxia. a Relative expression levels of CAIX mRNA in the tumors as determined by qPCR.
Error bars indicate SEM. **pG0.01. b Representative ex vivo FMT images of dissected FaDu-luc tumors 24 h after
HypoxiSense680 injection. c Quantification of HypoxiSense signals in individual dissected tumors. RT radiation therapy,
HBOT hyperbaric oxygen therapy.
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Fig. 4 Effect of HBOT on tumor malignancy parameters. a H&E staining of a tissue section of a representative FaDu-luc tumor
dissected from the floor of the mouth. All treatment groups show poorly to moderately differentiated squamous cell carcinoma.
b Detail of A. c Detail of A. d–g Relative expression levels of E-cadherin (d), Vimentin (e), Snail (f), and TGFβ1 (g) mRNA in the
tumors. RT radiation therapy, HBOT hyperbaric oxygen therapy. hIn vivo BLI of a tumor-bearing mouse at day 20 at an
emission wavelength of 560 nm showing lymph node metastases. i Photographic (left) and bioluminescent (right) images of
metastasized cervical lymph nodes. j H&E staining of a tissue section of a representative metastasized lymph node.
Table 1. Proliferation, apoptosis, and necrosis in FaDu tumors
Factor Control HBOT RT RT+HBOT
Proliferation (% Ki67-positive tumor cells)a 38.1±1.8 40.0±1.5 43.2±1.7 41.9±1.2
Apoptosis (# cells/mm2)a 30.6±2.9 24.9±2.4 22.2±3.9 19.0±4.1
Necrosis (% area)b 2.9 [0–28.0] 6.9 [0.5–27.5] 5.0 [0–42.1] 6.9 [0–31.0]
RT radiation therapy, HBOT hyperbaric oxygen therapy
aMean values±SEM
bMedian values [range]
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the fact that irradiation, in addition to killing tumor cells,
also damages endothelial cells [27, 28], resulting in a tumor
microenvironment that is less susceptible to HBOT-induced,
growth promoting stimuli. Although tumors grew faster in
HBOT-treated mice as compared to controls, the survival
time of these animals was not affected. Interestingly, the
bioluminescent signals of the tumors at the endpoints were
higher in the HBOT group, indicating that these mice
survived higher loads of viable tumor tissue. Also, in the
irradiated groups, in which the survival period was extended
by HBOT but the tumor growth rate was not affected, a
trend towards increased endpoint tumor load was noticed.
HBOT might affect the disturbed metabolic processes in the
body that lead to cancer-associated weight loss and in this
way increase survival rates. From a clinical point of view,
this is an interesting finding and future studies are warranted
to investigate this potential beneficial impact of HBOT.
Histological analyses could not reveal the factors that
underlie the accelerated tumor growth after HBOT. Small
and possibly transient influences of HBOT on vasculariza-
tion, proliferation, or cell death might have lead to the
observed growth effect. HBOT stimulates vessel develop-
ment in normal tissue and in wounds [3, 5] but its effect on
tumor vascularization is unclear. Tumors possess disorga-
nized and leaky tumor vessels which block adequate tissue
perfusion leading to the presence of hypoxic regions that are
associated with poor prognosis and treatment outcome [29,
30]. Normalization of the tumor vasculature is thought to
lead to less tumor hypoxia and is a goal of anti-angiogenic
therapies [9, 31]. In our HNSCC tumor model, in vivo
molecular imaging with the blood pool agent AngioSense
disclosed a higher vascular leakiness in tumors of HBOT-
treated animals. This is the first study exploring the effects
of HBOT on vascular permeability, indicating that HBOT
does not lead to normalization of blood vessels and might
even deteriorate tumor vascular quality.
To compare the hypoxic states of the tumors, the recently
developed HypoxiSense probe, which detects the protein
CAIX on the tumor cell surface, was employed. Due to
relatively low fluorescent signals, however, in vivo data
could not be obtained. In previous studies, this fluorescent
agent was successfully used in subcutaneous xenograft
tumors with volumes of 600–700 mm [3, 32]. In our
orthotopic model, the tumors in the floor of the mouth did
not grow beyond 250 mm3 and therefore signal detection
was probably hampered by optical properties such as
background absorption and scattering [33]. Nevertheless,
ex vivo, hypoxic regions were detected in a subset of tumors
and the data suggest that irradiated tumors were more
hypoxic than non-irradiated tumors and moreover, that
HBOT aggravated tumor hypoxia as well. It has been
demonstrated that HBOT increases the oxygen concentration
in tumor tissue during and shortly after treatment but this
effect is transient [34, 35]. The drop in oxygen level
following a HBOT session may lead to the induction of a
hypoxic response in the tumor tissue, by which CAIX
expression could be enhanced. This would correspond to
previous studies in which exposure to HBOT resulted in
increased levels of the hypoxia inducible factor HIF-1ɑ in
the liver and brain of rats [36–38]. It is also possible that
CAIX production was not stimulated by hypoxia, but by
inflammatory cytokines that are known for their ability to
induce HIF-1ɑ stabilization as well [39]. The fact that CAIX
mRNA levels were not found to be elevated in the dissected
tumors suggests that CAIX gene activation had been
transient, and that transcription had returned to normal
levels since the last HBOT session. In conclusion, our data
indicate that the use of intensive HBOT protocols does not
lead to long-term overall reduction of tumor hypoxic
responses.
The presence of cervical lymph node metastasis is an
important prognostic indicator for patients with HNSCC.
The current bioluminescent orthotopic tumor model allowed
us to monitor the consequences of treatment for the
development of lymph node metastases. Metastatic inci-
dence was increased from approximately 70 to 90 % in the
irradiated animals, but was not affected by HBOT. This
confirms previous experimental results obtained in different
cancer and animal models, in which stimulation of metas-
tasis by HBOT was not established either [16, 40–44].
Histopathological and molecular analysis of the tumors did
not reveal significant HBOT-induced changes in malignant
parameters. Epithelial-to-mesenchymal transition (EMT) is a
central mechanism of cancer metastasis whereby tumor cells
are reprogrammed, resulting in decreased adhesion and
enhanced migration and invasion [45–47]. The expression
of the hallmark molecules of EMT, the epithelial marker E-
cadherin, the mesenchymal marker Vimentin, and the EMT-
inducing factors Snail and TGFβ1 was not affected by
HBOT, indicating that there was no switch to more
aggressive tumors. Moen et al. [15] reported induction of
mesenchymal-to-epithelial transition (MET) by HBOT in a
mammary tumor model, but thus far there are no indications
for similar effects in squamous cell cancer.
Altogether, in this study, we found that HBOT stimulated
the growth of non-irradiated tumors and increased tumor
blood vessel leakiness and hypoxia. These are factors known
to promote aggressive tumor behavior and poorer treatment
outcome [10, 30]. On the other hand, HBOT was beneficial
for animal survival and no effects of HBOT were detected
on metastatic incidence, histological grade, and malignancy
Table 2. Incidence and rate of lymph node metastasis in mice with FaDu
tumors
Factor Control HBOT RT RT+
HBOT
Metastatic incidence 8/12 8/11 9/10 10/11
Metastatic percentage 67 % 72 % 90 % 91 %
Fisher’s exact test vs
control
1.000 0.323 0.317
RT radiation therapy, HBOT hyperbaric oxygen therapy
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markers, suggesting that the effects of HBOT on disease
outcome are limited and there might be no increased risk for
negative effects of HBOT in patients that were previously
subjected to radiation therapy. Previous experimental studies
on the effects of HBOT on tumor behavior thus far yielded
varying results [8, 11]. In mammary and glioma tumor
models, growth-inhibiting and anti-angiogenic effects were
reported using a HBOT schedule of 3 to 4 sessions per week
[13, 14, 48]. Studies using squamous cell cancer models did
not reveal effects of HBOT on tumor growth [16–20], except
for a recent study by Paniello et al. [21] who also observed
enhanced growth of xenografted HNSCC tumors in mice. In
these studies, daily HBOT sessions were applied, according
to the clinically used protocols for the management of
radiation-induced injury. Therefore, specific tumor charac-
teristics and HBOT time schedules might underlie the
different outcomes and need to be considered in future
studies.
Conclusions
The improved animal model and in vivo molecular imaging
methods used in this study disclosed influences of HBOT on
the growth rate, blood vessel quality, and hypoxic state of
squamous cell carcinoma and opens up possibilities to
further investigate the circumstances and conditions in
which HBOT can be safely used in cancer patients.
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